He reviewed the protocol four times before sending it to the committee. Not because anyone asked. Not because he'd found errors. Because something in his body wouldn't let him stop.

"I just want to make sure we have the data before we decide." A senior engineering director. Two decades in pharma. PhD. The kind of leader whose technical reviews were meticulous and whose team delivered consistently.

Reasonable. Responsible. Exactly what his role required.

I asked what would happen if he sent it after the second review. If he trusted his judgement and let it go.

His jaw tightened. His hands moved from the table to the arms of his chair. His body answered before his mind did.

It was not the protocol he was protecting.

In pharma, consensus is the currency of survival. Every decision moves through a committee. Every committee moves through a process. The process is the point — patient safety requires it, regulation demands it, and the leaders who get promoted are the ones who master thoroughness.

What nobody examines is what thoroughness does to the person practising it. Over twenty years, the caution that protects patients becomes structural. Total. It stops being something you do and becomes something you are. And the environment never asks you to notice the difference, because the environment is built on the same logic.

Prudence demands perfection. Caution fears the mistake. And tradition provides the rule book. A closed system with no exit and no reason to look for one.

Two leaders sit in the same pharma leadership team meeting. Same matrix. Same consensus culture. Same regulatory pressure. Entirely different fortresses.

He will not ask a question unless he already knows the answer. Questions are admissions. If it cannot be measured, it does not exist. And if it does not exist, he does not have to feel it.

She will not assert a position unless the room has already arrived there. She hedges: "I think maybe we could consider..." She frames her strategic thinking as team insight. Sharper language would violate the unspoken contract.

He sees her hedging and thinks: she doesn't have the data. She sees his certainty and thinks: he doesn't have the room. Both are running survival strategies built for this environment. Both are invisible to themselves.

When pressure arrives — AI adoption, restructuring, the compression of timelines that pharma has always resisted — the thoroughness that protected patients begins to protect something else.

The leader who built a career on careful, consensus-driven decisions encounters a situation that demands speed. The regulatory argument is ready: we cannot move faster, the process exists for a reason, patient safety requires diligence. All of that is true.

And underneath, a different sentence: if I move faster, I lose the structure that tells me I'm doing this right.

One of my clients, different engagement, put it plainly: "Some parts are perfectionists, some parts want to control things, some parts say it needs to be this way because if it's not, the whole world is going to collapse. And that part takes over most of the time."

That part doesn't announce when it's outlived its purpose. In a culture that rewards caution, nobody asks the question that matters: is the caution protecting the patient, or protecting you?

He never fully answered that question while we worked together. He got close a few times — the sessions where his hands relaxed, where his language loosened, where "the protocol" briefly became "my protocol" and the ownership changed the sentence.

Then the next committee cycle would start, and the fourth review would return.

But the question was in the room now. It didn't need his answer. It just needed him to keep hearing it.

...

Related

More from the coaching room